U.S. market Closed. Opens in 17 hours 19 minutes

STOK | Stoke Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue8.78M12.40MN/AN/AN/A
Cost of RevenueN/A3.54M2.23M1.93M450.00K
Gross Profit8.78M8.87M-2.23M-1.93M-450.00K
Operating Expenses123.55M116.76M86.06M53.04M35.68M
Selling, General & Admin41.32M38.92M31.90M20.85M11.91M
Research & Development82.23M77.84M54.17M32.20M23.76M
Other Operating ExpensesN/A167.00K140.00K57.00K2.00K
Operating Income-114.77M-104.36M-86.06M-53.04M-35.68M
Other Expenses / Income10.07M3.29M260.00K801.00K3.35M
Before Tax Income-104.70M-101.07M-85.81M-52.24M-32.33M
Income Tax ExpensesN/A-7.96M-1.09M-1.63M-3.80M
Net Income-104.70M-93.11M-84.71M-50.61M-28.52M
Interest ExpensesN/A3.12M120.00KN/AN/A
Basic Shares Outstanding43.99M38.90M36.74M33.49M17.97M
Diluted Shares Outstanding43.99M38.90M36.74M33.49M17.97M
EBITDA-112.30M-102.81M-83.58M-50.32M-35.23M
EBITDA Margin-1,279.09%-828.78%0.00%0.00%0.00%
EBIT-104.70M-97.94M-85.69M-52.24M-32.33M
EBIT Margin-1,192.47%-789.56%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙